Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On June 3, Obio Technology (Shanghai) Corp., Ltd. ("Obio Technology," stock code: 688238) and Shenzhen Innolmmune Co., Ltd. ("Shenzhen Innolmmune") officially signed a strategic cooperation agreement. According to the agreement,Obio Technology (Shanghai) Corp., Ltd. provides preclinical pharmaceutical research services for the TCR-T cell drug pipeline SIIT-T002 of Shenzhen Innolmmu Co., Ltd., ensuring the smooth progress of the pipeline's IND application. It also offers CMC services for subsequent IND applications related to a series of TCR-T cell drug product developments, including the production of retroviral vector and TCR-T cell product samples.Both parties will jointly develop safer, more effective, accessible, and affordable TCR-T cell drugs based on retroviral vectors, working together to create a bright future for cell therapy and benefit patients!
Shenzhen Innolmmu is an innovative organization dedicated to the research and development, transformation, and industrialization of tumor immunotherapy products.Possessing internationally leading key technology platforms for the discovery of tumor-specific antigens and innovative source technologies for the production and preparation of novel TCR-T cells.Over the years, staying true to its original aspiration and forging ahead, it has focused on the early-stage R&D and industrialization of retroviral vector and TCR-T cell products. Through the independent innovation of its R&D and production teams, as well as international cooperation, multiple sustainable and innovative R&D product pipelines have been established.Obio Technology focuses on providing one-stop CDMO services for drug developers in the gene and cell therapy field, ranging from preclinical research, CMC pharmaceutical studies, clinical sample production to large-scale commercial manufacturing, aiming to empower the R&D of gene and cell therapy drugs. CurrentlyObio Technology (Shanghai) Corp., Ltd. has 15 vector production lines, 20 cell production lines, and a freeze-drying and filling integrated formulation line adapted for gene and cell therapy products, which can meet the GMP production requirements of gene and cell therapy products at different scales, with its innovation level ranking among the top in the industry.In addition, Obio Technology (Shanghai) Corp., Ltd. possesses advanced experimental equipment and a diversified range of analytical technologies and testing platforms, covering every aspect of gene and cell therapy drug research, development, production, and testing, providing customers with high-quality products and services.
Mr. Huang Heqin, Chairman of Shenzhen Innolmmu Co., Ltd.Stated: "We are very pleased that after multiple exchanges and discussions between Shenzhen Innate Immunotherapy and Obio Technology, we are finally able to come together and successfully establish this cooperative partnership today. We highly commend Obio Technology's mission of 'Empowering Gene Therapy, Safeguarding Life and Health,' and we deeply recognize their strategic layout and technical expertise. Both parties have reached a strong consensus on the advantages of retroviral vectors and TCR-T cell immunotherapy. We believe this collaboration will contribute to the development of China’s cellular immunotherapy and bring hope to countless patients with advanced malignant solid tumors."
Obio Technology (Shanghai) Corp., Ltd. CEO Mr. Guodong Jia"We are very pleased to reach a strategic cooperation with Shenzhen Innolmmu Therapeutics. Both parties will jointly promote the application of retroviral vectors and TCR-T cell therapy. As a leading CRO/CDMO enterprise in the field of gene and cell therapy, we always pay attention to the progress in the global gene and cell therapy field and the demand for GMP production, continuously empowering the industry with efficient and high-quality service standards."About Shenzhen Innolmmune
Shenzhen Innolmmu Therapeutics Co., Ltd. was established in July 2016, located in Building C2, Life Science Park, International Biovalley, Dapeng New District, Shenzhen City, Guangdong Province. The company has been awarded the title of "Technology-based Small and Medium-sized Enterprise" for many consecutive years, and passed the National High-tech Enterprise certification in July 2023. The industry belongs to one of the future industries that are key fostered and developed by both Shenzhen City and Dapeng New District (Cell and Gene Industry). The team members mainly come from the "Shenzhen Overseas High-level Talent Innovation and Entrepreneurship Team" introduced globally by Shenzhen City, including internationally renowned leaders in the field of tumor immunology and high-level overseas talents under Shenzhen's "Peacock Plan." The company primarily focuses on the research and development, transformation, and industrialization of a series of products, such as TCR-T cell drugs for treating various types of advanced solid tumors.Obio Technology (Shanghai) Corp., Ltd. (Stock Code: 688238), established in 2013, is a biotechnology company focusing on the gene therapy field. It provides CRO services such as gene therapy vector development and gene function research for fundamental research in gene therapy. It also offers CDMO services including process development and testing, IND-CMC pharmaceutical research, and GMP production of clinical samples for the R&D of gene therapy drugs, such as recombinant virus vector drugs, oncolytic viruses, and CAR-T cell therapy products.
Source of the article: Obio Technology
